Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations | Zendy

Soraya L. Moghazeh | Zendy; X Pan | Zendy; T M Arain | Zendy; C. Kendall Stover | Zendy; James M. Musser | Zendy; Barry N. Kreiswirth | Zendy

Open Access

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

Author(s) -

Soraya L. Moghazeh,

X Pan,

T M Arain,

C. Kendall Stover,

James M. Musser,

Barry N. Kreiswirth

Publication year - 1996

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.40.11.2655

Subject(s) - rpob , rifapentine , antimycobacterial , rifampicin , mycobacterium tuberculosis , microbiology and biotechnology , biology , isoniazid , rifamycin , rifabutin , tuberculosis , virology , antibiotics , medicine , latent tuberculosis , clarithromycin , pathology

A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research